Jean-Jacques Bienaimé (BioMarin via Youtube)

Look­ing to win back in­vestor con­fi­dence, Bio­Marin preps for its ‘largest launch’

Bio­Marin is ready to launch the first drug to treat achon­dropla­sia, the most com­mon form of dwarfism, in Vox­zo­go – it just needs an FDA green­light.

The US com­mer­cial team is plan­ning for Vox­zo­go’s launch at the end of the year with an “ex­pe­ri­enced” sales force al­ready in place, Bio­Marin ex­ecs told an­a­lysts in its quar­ter­ly call this week. The bio­phar­ma is al­so work­ing with the FDA on late-stage la­bel­ing and post-mar­ket­ing re­quire­ments.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.